These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 16909975)

  • 1. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
    Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compensator-based intensity-modulated radiotherapy in head and neck cancer: our experience in achieving dosimetric parameters and their clinical correlation.
    Nangia S; Chufal KS; Arivazhagan V; Srinivas P; Tyagi A; Ghosh D
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):485-92. PubMed ID: 16909973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
    Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
    Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
    Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life.
    Chen WC; Lai CH; Lee TF; Hung CH; Liu KC; Tsai MF; Wang WH; Chen H; Fang FM; Chen MF
    Oral Oncol; 2013 Jan; 49(1):42-8. PubMed ID: 22854066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
    Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
    J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigations on parotid gland recovery after IMRT in head and neck tumor patients.
    Stock M; Dörr W; Stromberger C; Mock U; Koizar S; Pötter R; Georg D
    Strahlenther Onkol; 2010 Dec; 186(12):665-71. PubMed ID: 21136030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study on the impact of patient-related parameters in the ability to spare parotid glands by intensity-modulated radiotherapy for head and neck squamous cell carcinomas.
    Bandlamudi BP; Sharan K; Yathiraj PH; Singh A; Reddy A; Fernandes DJ; Srinivasa VM
    J Cancer Res Ther; 2018; 14(6):1220-1224. PubMed ID: 30488833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results.
    Eisbruch A; Ship JA; Martel MK; Ten Haken RK; Marsh LH; Wolf GT; Esclamado RM; Bradford CR; Terrell JE; Gebarski SS; Lichter AS
    Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):469-80. PubMed ID: 8892473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose and volume impact on radiation-induced xerostomia.
    Marmiroli L; Salvi G; Caiazza A; Di Rienzo L; Massaccesi M; Murino P; Macchia G
    Rays; 2005; 30(2):145-8. PubMed ID: 16294907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life.
    van Rij CM; Oughlane-Heemsbergen WD; Ackerstaff AH; Lamers EA; Balm AJ; Rasch CR
    Radiat Oncol; 2008 Dec; 3():41. PubMed ID: 19068126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volumetric changes of the parotid gland during IMRT based on mid-treatment imaging: implications for parotid stem cell sparing strategies in head and neck cancer.
    Gjini M; Ahmed S; Kalnicki S; Tomé WA; Garg MK; Kabarriti R; Brodin NP
    Acta Oncol; 2022 Sep; 61(9):1069-1074. PubMed ID: 35978529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.